The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes

Netherlands Journal of Medicine

Volumn 70, Issue 10, 2012, Pages 436-443

  van der Klauw, M M ^a   Wolffenbuttel, B H R ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Combination; Diabetes mellitus; GLP 1 analogue; Insulin; Review

Indexed keywords

C PEPTIDE; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA;

APPETITE DISORDER; BODY WEIGHT; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEADACHE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; META ANALYSIS (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SIDE EFFECT; THYROID CARCINOMA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN RESISTANCE; TREATMENT OUTCOME;

EID: 84871418176     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;10:CD006423.
2. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-4.
3. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor analogues on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
4. Jazet IM, de Craen AJ, van Schie EM, Meinders AE. Sustained beneficial metabolic effects 18 months after a 30-day very low calorie diet in severely obese, insulin-treated patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;77:70-6.
5. Rosenstock J, Fonseca V. Missing the point: substituting exenatide for non-optimized insulin: going from bad to worse! (Editorial). Diabetes Care. 2007;30:2972-3.
6. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:3082-9.
7. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103-12.
8. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33:1509-15.
9. Rosenstock J, Shenouda SK, Bergenstal RM, et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care. 2012;35:955-8.
10. De Vries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1c targets. Diabetes Care. 2012;35:1446-54.
11. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13:444-50.
12. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract. 2008;14:285-92.
13. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009;31:1511-23.
14. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM. 2010;103:687-94.
15. Lane WL, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirement. Diabetes Technol Ther. 2011;13:592-5.
16. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab. 2011;13:703-10.
17. Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2012;28:439-46.
18. Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract. 2012;18:17-25.
19. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes. 2012;6:41-6.
20. Thong KY, Jose B, Blann AD, et al. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract. 2011;93:e87-e91.
21. Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010;33:1294-6.
22. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165:77-84.
23. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual 1-cell function. Diabetes Care. 2011;34:1463-8.
24. Ryder REJ, Thong KY, Cull ML, Mills AP, Walton C, Winocour PH. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Practical Diabetes Int. 2010;27:352-7b.
25. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonistsavailable efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011;13:394-407.